Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Optimer Pharmaceuticals
December 17, 2013
Cubist turns positive on good news from gram-negative antibiotic
August 29, 2013
Upcoming events: first look at Dificid in new patient population
July 31, 2013
Cubist right to inject caution into much-needed acquisition spree
December 09, 2011
Pharmacyclics strikes most lucrative single-product deal of 2011
August 18, 2011
Encouraging signs from quality of new drugs approved so far in 2011
July 26, 2011
Glaxo emerges as big spender as external pipeline grows
April 06, 2011
Panel vote and marketing deal two rays of sunshine for Optimer
February 08, 2011
Event - Partnership a prelude to regulators' judgement for Optimer
October 21, 2010
Partnering opportunities abound in oncology, CNS and infectious diseases
February 15, 2010
Optimer and investors playing the waiting game
January 18, 2010
Event - Optimer investors see reasons for optimism over phase III data
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
January 17, 2023
JP Morgan Healthcare Conference 2023
January 12, 2023
Evaluate Vantage 2023 Preview Infographic
Editor's Picks
January 03, 2023
The biggest-selling pharma companies of 2023
January 05, 2023
The biggest-selling drugs of 2023
January 05, 2023
Flotations fail to bounce back
January 06, 2023
Fate runs out of excuses
December 15, 2022
Ash 2022 roundup
